Compare BFC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFC | IOVA |
|---|---|---|
| Founded | 1894 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2018 | 2008 |
| Metric | BFC | IOVA |
|---|---|---|
| Price | $155.29 | $4.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $157.00 | $9.00 |
| AVG Volume (30 Days) | 82.1K | ★ 15.7M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | 11.23 | ★ 14.84 |
| EPS | ★ 1.78 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.67 | $47.74 |
| Revenue Next Year | $2.01 | $40.31 |
| P/E Ratio | $85.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $115.29 | $1.76 |
| 52 Week High | $154.42 | $5.64 |
| Indicator | BFC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 64.11 | 46.11 |
| Support Level | $134.81 | $3.51 |
| Resistance Level | N/A | $4.45 |
| Average True Range (ATR) | 4.97 | 0.45 |
| MACD | 0.53 | -0.10 |
| Stochastic Oscillator | 91.09 | 28.72 |
Bank First Corp is a United States-based company engaged in providing financial services, a full range of consumer and commercial financial institution services to individuals and businesses, including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.